Physician profile
Clifford Simon
NPI 1487668299
$3,159.78
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $413 · 2021: $577 · 2022: $333 · 2023: $384 · 2024: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $470.15 | 2019-2024 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.06 | 2019-2023 | Spiriva Respimat |
| Novo Nordisk INC | $266.45 | 2019-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $185.54 | 2019-2022 | |
| Amgen INC. | $184.65 | 2019-2023 | Prolia, Evenity |
| Shire North American Group INC | $160.30 | 2019 | |
| Mannkind Corporation | $132.97 | 2019-2024 | |
| Philips North America LLC | $121.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $102.21 | 2019-2020 | |
| Amarin Pharma, INC. | $69.10 | 2019-2021 | |
| Abbvie INC. | $64.23 | 2019-2022 | |
| Grifols USA, LLC | $59.85 | 2019-2023 | Prolastin-C Liquid |
| Xeris Pharmaceuticals, INC. | $59.69 | 2021-2023 | Gvoke Hypopen |
| Genzyme Corporation | $56.15 | 2019-2021 | |
| Harmony Biosciences LLC | $54.30 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.